Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center (“Lahey”).

This collaboration will advance systems biology and computational analyses in the field of Inflammatory Bowel Diseases (IBD).

Athos Therapeutics will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples with the following clinical descriptions: Crohn’s disease (CD) active, CD inactive (in remission), Ulcerative colitis (UC) active, UC inactive (in remission), and controls. The results of the biopsy analyses will be correlated with detailed clinical information including the patient’s age, sex, disease location, prior treatments, and status.

“We are excited to collaborate with Dr. Randall Pellish and his team to identify novel molecular targets and subtypes of IBD patients,” said Dimitrios Iliopoulos, PhD, MBA, President & CEO. “Lahey’s IBD patient biomaterials will be fed into our Athos Learning Computational Ensemble

(ALCE) engine to further elucidate the complexity of IBD and the heterogeneity of drug responses.”

“Athos Therapeutics is developing a precision medicine approach to the treatment of IBD and other autoimmune disorders,” said Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO. “The availability of high-quality tissue resources linked to verified clinical data, which forms the basis for our collaboration with Lahey Hospital, will make this possible and allow for the identification of new disease sub-types and for the identification of novel drug targets.”

“We are very excited about our research initiatives with Athos Therapeutics,” said Randall Pellish, MD, Director, Lahey Inflammatory Bowel Disease Center, Division of Gastroenterology, Lahey Hospital and Medical Center. “This collaborative research project will allow us to work on vital questions addressing new ways of classifying and treating inflammatory bowel disease with the goal of developing meaningful, perhaps paradigm shifting, treatment strategies.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine